SM-020
Phase 2Small molecule
SM-020 is one of 71 small molecule programs targeting Skin Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
131 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Actemra
RochePhase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Empaveli
Apellis PharmaceuticalsPhase 3
CAB LA
GSKPhase 3
Tagrisso
AstraZenecaPhase 2
Cytosar
TevaPhase 2
B/F/TAF
GileadPhase 3
Selzentry
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Keratosis2 trials
Skin Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SM-020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDermBiont, Inc.